Halozyme Therapeutics | HALO - Sales Revenues


Halozyme Therapeutics reported $377M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amarin USD 49.22M 451K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Cytokinetics USD 19.35M 1.59M Mar/2026
DBV Technologies USD 2.77M 1.31M Sep/2025
Eli Lilly USD 19.8B 500M Mar/2026
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Intrexon USD 717K 511K Jun/2024
Ionis Pharmaceuticals USD 246M 43M Mar/2026
MannKind USD 90.2M 21.76M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
United Therapeutics USD 781.5M 8.7M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024